irinotecan hydrochloride liposome + fluorouracil + leucovorin + immunotherapy

Irinotecan hydrochloride liposome (marketed as Onivyde) is a topoisomerase 1 inhibitor encapsulated in a lipid bilayer vesicle (liposome), designed to enhance delivery and prolong exposure of the active drug and its metabolite SN-38 to tumor cells. It is used in combination with fluorouracil (a pyrimidine analog antimetabolite that inhibits thymidylate synthase) and leucovorin (which enhances the effects of fluorouracil) for the treatment of metastatic pancreatic adenocarcinoma, particularly after progression on gemcitabine-based therapy or as first-line therapy with additional agents. The mechanism involves inhibition of DNA replication by stabilizing topoisomerase I-DNA complexes, leading to double-strand DNA breaks and cell death. Immunotherapy refers broadly to agents that stimulate or restore the immune system's ability to fight cancer; specific immunotherapeutic agent(s) are not specified here[1][3][4][5][8].

Brand names

Onivyde

Other names

irinotecan liposome injectionirinotecan hydrochloride liposome5-fluorouracil5-FUleucovorin